Primer: Sirius Therapeutics (ST HK) - Aug 2026
Sirius Therapeutics is a clinical-stage biotechnology company with a promising pipeline of first-in-class and best-in-class siRNA therapies...
97 Views
Sirius (éť–ĺ› ç”źç‰©) Pre-IPO: Pipeline Prioritization and Competitor Updates
Sirius update note: SRSD107 broadened to seven FXI indications, SRSD216 Phase 3 pulled into H2 '27. Competitive field tightens across FXI, Lp(a)...
291 Views
Pre-IPO Sirius Therapeutics - The Pipeline and the Concerns Behind
SRSD107 and SRSD216 have blockbuster potential,but will face R&D failure risk and uncertainties in commercialization.Sirius' lack of commercialized...
290 Views
ECM Weekly (13 October 2025)- LG India, Tata Capital, Rubicon, Canara, FineToday, Maynilad, Kokusai
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
885 Views
Sirius (éť–ĺ› ) Pre-IPO: Credible SiRNA Products
​China's Sirius Therapeutics plans to raise $100 million through a Hong Kong listing. The insight discusses their core products, pre-IPO investors,...
870 Views
No more insights